Mike Penning: To ask the Secretary of State for Health and Social Care, with reference to the oral contribution of the Parliamentary Under-Secretary of State for Health and Social Care on 20 May 2019, Official Report, column, 571, what plans he has to include observational trials in building up the existing evidence-base.
Mike Penning: To ask the Secretary of State for Health and Social Care, what assessment he has made of the accuracy of evidence base on the cost-effectiveness of medical cannabis.
Tonia Antoniazzi: Last Thursday, I travelled to the Netherlands with Teagan Appleby’s mother, Emma, to pick up the medical cannabis that has reduced Teagan’s seizures from 300 to four a day. In the absence of NHS prescribing, parents like Emma are having to go abroad, or pay exorbitant import and pharmacy charges. Emma had a UK prescription, so met the criteria presented to her at border control to the...
Seema Kennedy: Health Education England has been commissioned to produce e-learning resources for clinicians and healthcare professionals to raise awareness of the regulation, guidance and evidence around cannabis-based products for medicinal use, and to build confidence in appropriate use and prescribing of such products. These resources will shortly be available and will be accessible by all healthcare...
Mike Penning: ...ask the Secretary of State for Health and Social Care, when he plans to publish the interim report produced by NHS England to identify the barriers that are blocking access to prescribed medicinal cannabis by patients.
Ian Austin: ...Care, with reference to his oral contribution of 8 April 2019, Official Report, column 36, what the timetable is for making available a public register of specialist clinicians who can prescribe cannabis-based medicines.
Ronnie Cowan: ...UK. Rather than people having to fight for access on a case-by-case basis, will the Prime Minister apply some common sense, show a soupçon of compassion and do everything she can to make medical cannabis available to the many people who are suffering and to ensure that those who can benefit do?
Mike Penning: To ask the Secretary of State for Health and Social Care, what the process will be for patients that are refused a prescription for medical cannabis oil by their second opinion; and will he make a statement.
Tulip Siddiq: ...Home Department, what assessment he has made of the implications for his Department's policy of the recommendation of the World Health Organisation's Expert Committee on Drug Dependence (ECDD) that cannabis and cannabis resin be deleted from Schedule IV of the 1961 Single Convention on Narcotic Drugs; and whether the Government plans to vote in accordance with the recommendation of the ECDD.
Mike Penning: ...really do not know the full position yet because, as the Minister has said, we have to do more work. However, in quite a lot of specific cases of paediatric epilepsy with seizures, it appears that cannabis oil makes a difference to the quality of people’s lives. We were sent here not to chat for the sake of it, but to make a difference to people’s lives, and I hope that is exactly what...
Andrea Leadsom: ...business for the week commencing 20 May will include: Monday 20 May—Proceedings on the Non-Domestic Rating (Preparation for Digital Services) Bill, followed by a debate on a motion on medical cannabis under prescription. The subject of this debate was determined by the Backbench Business Committee. Tuesday 21 May—Second Reading of the Parliamentary Buildings (Restoration and...
Jeff Smith: On the subject of drugs, may I just make a suggestion? If we were to legalise and regulate the cannabis trade, we could raise £1 billion a year to put into policing crime. We could also make the product safer and take the trade out of the hands of organised criminal gangs. By regulating our cannabis trade in the way we do with alcohol, we would make our streets safer.
Tom Brake: To ask the Secretary of State for Health and Social Care, what steps his Department is taking to (a) increase public consultation on the creation of interim guidance for medicinal cannabis and (b) ensure patient and health professional organisations are engaged in the Department’s working group on medicinal cannabis.
Jo Stevens: To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 24 April 2019 to Question 244142 on Cannabis: Medical Treatments, whether his Department defines Naboline as a cannabis imitating rather than cannabis derived product.
Jo Stevens: To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 24 April 2019 to Question 244142 on Cannabis: Medical Treatments, whether his Department is aware of any instances of (a) CBD and (b) THC being prescribed by the NHS since 1 January 2019.
Baroness Meacher: ...speak about the potential to prevent some disabilities—obviously a limited number, but some—and to ameliorate many others, if only the UK could agree to establish a special category for medical cannabis within our regulatory framework. This sounds a narrow subject, but actually it has huge implications for many people. First, why should cannabis be treated differently from other...
Mike Penning: To ask the Secretary of State for Health and Social Care, what the timeframe is for the process evaluation being undertaken by the NHS on prescribing cannabis-based products for medical use; and if he will he make a statement.
Mike Penning: ..., how the National Institute for Health Research will identify patients with severe intractable epilepsy to use as a placebo in research into the safety and clinical efficacy and effectiveness of cannabis-based products for medical use in humans.
Mike Penning: ...Secretary of State for Health and Social Care, with reference to his oral contribution of 8 April 2019, Official Report, column 26, how the system of second opinions on the prescribing of medical cannabis oil will be organised; and if he will make a statement.